Pancreatic cancer-associated diabetes mellitus is characterized by reduced β-cell secretory capacity, rather than insulin resistance. 2022

Jiantong Bao, and Dechen Liu, and Jinfang Sun, and Xianghui Su, and Hao Cheng, and Liang Qi, and Yidi Zhang, and Yingqi Lv, and Zheng Ye, and Xuebing Yu, and Qiong Wei, and Yudong Qiu, and Jianhua Su, and Ling Li
Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.

OBJECTIVE The early distinction of pancreatic cancer associated diabetes (PaCDM) in patients with elderly diabetes is critical. However, PaCDM and type 2 diabetes mellitus (T2DM) remain indistinguishable. We aim to address the differences between the pancreatic and gut endocrine hormones of patients with PaCDM and T2DM. METHODS A total of 44 participants underwent mixed meal tolerance test (MMTT). Fasting and postprandial concentrations of insulin, C-peptide, glucagon, pancreatic polypeptide (PP), glucagon-like peptide-1 (GLP-1), and gastric inhibitory peptide (GIP) were measured. Insulin sensitivity and secretion indices were calculated. One-way ANOVA with post-hoc analysis was used for statistical analysis. RESULTS Insulin and C-peptide responses to MMTT were blunted in PaCDM patients compared with T2DM. Baseline concentrations and AUCs differed. PaCDM patients showed lower insulin secretion capacity but better insulin sensitivity than T2DM patients. The peak concentration and AUC of PP in T2DM group were higher than healthy controls, but in accordance with PaCDM. PaCDM patients presented lower baseline GLP-1 concentration than T2DM patients. No between-group differences were found for glucagon and GIP. CONCLUSIONS PaCDM patients had a lower baseline and postprandial insulin and C-peptide secretion than T2DM patients. Reduced insulin secretion and improved peripheral sensitivity were found in PaCDM patients compared with T2DM.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005749 Gastric Inhibitory Polypeptide A gastrointestinal peptide hormone of about 43-amino acids. It is found to be a potent stimulator of INSULIN secretion and a relatively poor inhibitor of GASTRIC ACID secretion. Glucose-Dependent Insulinotropic Peptide,Gastric-Inhibitory Polypeptide,Glucose Dependent Insulinotropic Peptide,Glucose-Dependent Insulin-Releasing Peptide,Glucose Dependent Insulin Releasing Peptide,Inhibitory Polypeptide, Gastric,Insulin-Releasing Peptide, Glucose-Dependent,Insulinotropic Peptide, Glucose-Dependent,Peptide, Glucose-Dependent Insulin-Releasing,Peptide, Glucose-Dependent Insulinotropic,Polypeptide, Gastric Inhibitory,Polypeptide, Gastric-Inhibitory
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Jiantong Bao, and Dechen Liu, and Jinfang Sun, and Xianghui Su, and Hao Cheng, and Liang Qi, and Yidi Zhang, and Yingqi Lv, and Zheng Ye, and Xuebing Yu, and Qiong Wei, and Yudong Qiu, and Jianhua Su, and Ling Li
September 2016, Endocrinology and metabolism (Seoul, Korea),
Jiantong Bao, and Dechen Liu, and Jinfang Sun, and Xianghui Su, and Hao Cheng, and Liang Qi, and Yidi Zhang, and Yingqi Lv, and Zheng Ye, and Xuebing Yu, and Qiong Wei, and Yudong Qiu, and Jianhua Su, and Ling Li
May 1979, Human pathology,
Jiantong Bao, and Dechen Liu, and Jinfang Sun, and Xianghui Su, and Hao Cheng, and Liang Qi, and Yidi Zhang, and Yingqi Lv, and Zheng Ye, and Xuebing Yu, and Qiong Wei, and Yudong Qiu, and Jianhua Su, and Ling Li
February 2022, Biomolecules,
Jiantong Bao, and Dechen Liu, and Jinfang Sun, and Xianghui Su, and Hao Cheng, and Liang Qi, and Yidi Zhang, and Yingqi Lv, and Zheng Ye, and Xuebing Yu, and Qiong Wei, and Yudong Qiu, and Jianhua Su, and Ling Li
May 2001, Transplantation,
Jiantong Bao, and Dechen Liu, and Jinfang Sun, and Xianghui Su, and Hao Cheng, and Liang Qi, and Yidi Zhang, and Yingqi Lv, and Zheng Ye, and Xuebing Yu, and Qiong Wei, and Yudong Qiu, and Jianhua Su, and Ling Li
December 2018, Heliyon,
Jiantong Bao, and Dechen Liu, and Jinfang Sun, and Xianghui Su, and Hao Cheng, and Liang Qi, and Yidi Zhang, and Yingqi Lv, and Zheng Ye, and Xuebing Yu, and Qiong Wei, and Yudong Qiu, and Jianhua Su, and Ling Li
April 2020, Pest management science,
Jiantong Bao, and Dechen Liu, and Jinfang Sun, and Xianghui Su, and Hao Cheng, and Liang Qi, and Yidi Zhang, and Yingqi Lv, and Zheng Ye, and Xuebing Yu, and Qiong Wei, and Yudong Qiu, and Jianhua Su, and Ling Li
January 2019, Diabetes,
Jiantong Bao, and Dechen Liu, and Jinfang Sun, and Xianghui Su, and Hao Cheng, and Liang Qi, and Yidi Zhang, and Yingqi Lv, and Zheng Ye, and Xuebing Yu, and Qiong Wei, and Yudong Qiu, and Jianhua Su, and Ling Li
October 2012, European journal of endocrinology,
Jiantong Bao, and Dechen Liu, and Jinfang Sun, and Xianghui Su, and Hao Cheng, and Liang Qi, and Yidi Zhang, and Yingqi Lv, and Zheng Ye, and Xuebing Yu, and Qiong Wei, and Yudong Qiu, and Jianhua Su, and Ling Li
January 1998, Diabetes,
Jiantong Bao, and Dechen Liu, and Jinfang Sun, and Xianghui Su, and Hao Cheng, and Liang Qi, and Yidi Zhang, and Yingqi Lv, and Zheng Ye, and Xuebing Yu, and Qiong Wei, and Yudong Qiu, and Jianhua Su, and Ling Li
March 2010, Gastroenterology,
Copied contents to your clipboard!